Role of Ticlopidine on Adriamycin-Induced Nephropathy

Abstract

The effect of ticlopidine on rats with adriamycin nephropathy was observed during 26 weeks. In the ticlopidine-treated nephrotic animals (TNG), proteinuria was less than in the untreated nephrotic animals (NG), but this difference was significant only at week 6 (TNG = 47.27 ± 16.52 versus NG = 100.08 ± 13.83 mg/24h, p < 0.01) and week 26 (TNG =157.00 ± 28.73 versus NG = 217.00 ± 21.73 mg/24h, p < 0.01) after ADR injection. NG presented severe tubulointerstitial abnormalities with a tubulointerstitial lesion index of 3+. No diffience in glomerular lesions was observed among the groups (NG median = 6%. TNG median = 4% and TCG median = 2%). The tubulointerstitial lesion index of TNG was less intense (median = 2+) but not different from those of the control groups (CG median = 1+; TCG median = 0+) nor NG (median = 3+). We concluded that the treatment with ticlopidine produced some partially beneficial effects but did not prevent the devdopment of adriamycin-induced nephropathy.

Key Words:

• Adriamycin nephropathy
• Proteinuria
• Antiplatelet agent
• Ticlopidine
• Progression of renal disease